Baiyunshan clarified the media reports: the follow-up needs to carry out further related work on the product.

1, Guangzhou Baiyunshan Hutchison Whampoa Chinese Medicine Co., Ltd. ("Baiyunshan and Huang Company") for the Company's 50% shareholding of the joint venture, not included in the scope of the company's merger, the Company's use of long-term equity investment equity method accounting.
the company is mainly engaged in the production and sales of Chinese medicine and drug research and development, the main products include plate blue root particles, compound dansin tablets, compound plate blue root particles and so on.
The relevant conclusions involved in the media reports are only the experimental results of the anti-new coronavirus in vitro screening conducted by the team of Zhong Nanshan academicians for the blue root particles of Baiyunshan and Huang's compound plate, and further related work is needed for the product.
2, the domestic plate blue root product market situation At present, plate blue root products in the domestic market has been fully competitive products, plate blue root particles, compound plate blue root particles have been approved a large number of symbols (as shown in the table below), plate blue root products are not the company or its affiliated enterprises exclusive production varieties.
: (1) The above approval number is sourced from the official website of the State Drug Administration;
3, plate blue root products on the performance of listed companies At present, the company and its subsidiaries, joint ventures only Baiyunshan and Huang company production and sales of blue root products.
2019, the Company's investment income from Baiyunshan and Huang was RMB67.9603 million, accounting for approximately 1.65% of the Company's total profits for the year, and RMB35.9982 million in the first half of 2020, accounting for approximately 1.59% of the Company's total current profit.
Baiyunshan and Huang's sales revenue for 2019 was RMB10,910.07 million, accounting for 7.23% of the company's sales revenue for the year, and RMB75.5461 million for the first half of 2020, accounting for 8.35% of the company's sales revenue for the same period.
of the blue root particles of the compound plate is not expected to have a significant impact on the Company's operating results.
.